{
    "clinical_study": {
        "@rank": "40259", 
        "arm_group": [
            {
                "arm_group_label": "Ticagrelor mashed pills", 
                "arm_group_type": "Experimental", 
                "description": "Ticagrelor loading dose (LD) 180 mg as mashed pills"
            }, 
            {
                "arm_group_label": "Ticagrelor integral pills", 
                "arm_group_type": "Active Comparator", 
                "description": "Ticagrelor loading dose (LD) 180 mg as integral pills"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the Mashed Or Just Integral pill of TicagrelOr (MOJITO) study is to evaluate the\n      superiority of Ticagrelor 180 mg LD mashed pill versus Ticagrelor 180 mg LD integral pill\n      both orally administrated in decreasing residual platelet reactivity 1 hour after the\n      administration among 70 patients with STEMI (ST segment elevation myocardial infarction)\n      undergoing PPCI with bivalirudin monotherapy."
        }, 
        "brief_title": "Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Coronary Syndrome", 
            "Adverse Reaction to Antiplatelet Agent"
        ], 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients presenting within 12 hours from the onset of symptoms with STEMI\n\n          -  Informed, written consent\n\n        Exclusion Criteria:\n\n          -  Age < 18 years or Age > 75 years\n\n          -  Active bleeding; bleeding diathesis; coagulopathy\n\n          -  Increased risk of bradycardiac events\n\n          -  History of gastrointestinal or genitourinary bleeding <2 months\n\n          -  Major surgery in the last 6 weeks\n\n          -  History of intracranial bleeding or structural abnormalities\n\n          -  Suspected aortic dissection\n\n          -  Any other condition that may put the patient at risk or influence study results or\n             investigator's opinion (severe hemodynamic instability, known malignancies or other\n             comorbid conditions with life expectancy <1 year)\n\n          -  Administration in the week before the index event of clopidogrel, ticlopidine,\n             prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or\n             fondaparinux .\n\n          -  Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers,\n             CYP3A with narrow therapeutic windows\n\n          -  Known relevant hematological deviations: Hb <10 g/dl, Thrombi. <100x10^9/l\n\n          -  Use of coumadin derivatives within the last 7 days\n\n          -  Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine\n\n          -  Known severe liver disease, severe renal failure\n\n          -  Known allergy to the study medications\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992523", 
            "org_study_id": "MOJITO Study"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ticagrelor mashed pills", 
                "description": "The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.", 
                "intervention_name": "Ticagrelor mashed pills", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ticagrelor integral pills", 
                "description": "The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).", 
                "intervention_name": "Ticagrelor integral pills", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptives, Oral", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ticagrelor", 
            "antiplatelet", 
            "Acute Coronary Syndrome"
        ], 
        "lastchanged_date": "February 13, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dalex@med.upatras.gr", 
                    "last_name": "Dimitrios Alexopoulos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Patras", 
                        "country": "Greece"
                    }, 
                    "name": "Department of Cardiology, Patras University Hospital"
                }, 
                "investigator": {
                    "last_name": "Dimitrios Alexopoulos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "parodiguido@gmail.com", 
                    "last_name": "Guido Parodi, MD", 
                    "phone": "+390557947732"
                }, 
                "facility": {
                    "address": {
                        "city": "Florence", 
                        "country": "Italy"
                    }, 
                    "name": "Careggi Hospital"
                }, 
                "investigator": {
                    "last_name": "Guido Parodi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Greece", 
                "Italy"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )", 
        "overall_contact": {
            "email": "parodiguido@gmail.com", 
            "last_name": "Guido Parodi, MD", 
            "phone": "+390557947732"
        }, 
        "overall_official": [
            {
                "affiliation": "Careggi Hospital, Division of Invasive Cardiology", 
                "last_name": "Guido Parodi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Careggi Hospital, Division of Invasive Cardiology", 
                "last_name": "David Antoniucci, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "residual platelet reactivity by Platelet Reactivity Units (PRU) VerifyNow 1 hour after ticagrelor LD.", 
            "measure": "residual platelet reactivity", 
            "safety_issue": "No", 
            "time_frame": "1 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992523"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Careggi Hospital", 
            "investigator_full_name": "David Antoniucci", 
            "investigator_title": "Director, Division of Invasive Cardiology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The percent of patients with a high residual platelet reactivity (PRU > 208) 1 hour and 2 hours after ticagrelor LD.", 
                "measure": "high residual platelet reactivity", 
                "safety_issue": "No", 
                "time_frame": "1, 2 hours"
            }, 
            {
                "description": "Major, minor, minimal bleeding (TIMI criteria) events", 
                "measure": "Bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "48 hours"
            }, 
            {
                "description": "Occurrence of dyspnoea and/or symptomatic bradycardia", 
                "measure": "Dyspnoea and/or symptomatic bradycardia", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Careggi Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "AstraZeneca", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "ARCARD ONLUS Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "David Antoniucci", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}